Progress in Heart Failure Management?
2000; Lippincott Williams & Wilkins; Volume: 102; Issue: 10 Linguagem: Inglês
10.1161/01.cir.102.10.1076
ISSN1524-4539
Autores Tópico(s)Cardiac pacing and defibrillation studies
ResumoHomeCirculationVol. 102, No. 10Progress in Heart Failure Management? Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBProgress in Heart Failure Management? Lessons from the Real World Marvin A. Konstam Marvin A. KonstamMarvin A. Konstam From the Division of Cardiology, New England Medical Center and Tufts University, Boston, Mass. Originally published5 Sep 2000https://doi.org/10.1161/01.CIR.102.10.1076Circulation. 2000;102:1076–1078In recent years, we have learned a great deal about the pathophysiology of heart failure, and we have demonstrated a significant potential for improved clinical outcomes with medical treatments. However, it is important to continually gauge the impact that this incremental knowledge has had on health outcomes in the real world, within populations beyond those enrolled in clinical trials. The study by MacIntyre et al,1 which examines 66 547 consecutive patients with first-time admissions for heart failure in Scotland, provides an important new look at the population of patients with this condition. It offers an opportunity to grade our accomplishments and to identify new approaches required to improve outcomes further.This group studied an elderly population (median age, 72 years in men and 78 years in women), evenly distributed between the sexes, with a poor prognosis (1-year mortality, 44.5%). However, the authors identified modest but encouraging improvement in outcomes over the 10-year observation period. In these findings, we see reason for optimism but also reason for concern that our clinical trials are leaving gaps in our knowledge and are not realizing their full potential for translation into improved public health.For their analysis, MacIntyre et al1 used an imperfect, yet unique and valuable national database. Databases derived from clinical trials or registries2 have the advantage of containing more detailed clinical information; however, the selection process inherent in their construction limit their usefulness in providing a true reflection of heart failure across the population. Furthermore, no such information set has been accumulated over a time frame sufficient to judge longitudinal changes in outcome. Administrative databases, although limited in their clinical content, may have less of a selection bias, and they can provide uniform information across a broad population over a long time frame. In the United States, the value of such administrative databases is limited because no single payer covers an entire geographic population across the entire range of ages. Population-based analyses345 offer a more uniform, unbiased examination and have the advantage of tracking the onset of heart failure within a population. However, such databases have tended to yield far fewer cases of heart failure than those tracked by MacIntyre et al.1The Scottish National Health Service database has 2 major limitations. First, it lacks extensive clinical information, which would help characterize the population and help eliminate patients in whom the diagnosis was erroneous. Second, it includes only those patients hospitalized for heart failure and tracks outcomes from the time of initial hospitalization. These factors must be considered in comparing outcomes with those in other populations, including clinical trials. Nevertheless, this database, which covers every hospitalization across an entire country, is powerful in its size and completeness, and the findings provide several unique and important insights.The populations enrolled in the heart failure trials with the greatest impact on present treatment (Table)67891011121314 have sharp contrasts with the characteristics of the population observed by MacIntyre et al.1 Clinical trials have largely been conducted in white, male populations with mean ages of ≈60 years. Although the racial characteristics of the MacIntyre study reflect those of Scotland, the findings of an older and more sex-balanced population are likely typical of the heart failure populations within most developed countries. Although partly driven by ejection fraction enrollment criteria, disparities between clinical trial populations and those of the "real world" also reflect the nature of patients presenting themselves to clinical trial sites.These disparities leave us in a quandary. There exists some physiological rationale to anticipate differences in responses to such agents as angiotensin-converting enzyme (ACE) inhibitors and β-blockers across ages, sexes, and races. However, the data derived from the trials of these agents are insufficient to either prove or disprove such differences. The results of these trials provide less than convincing evidence for the benefit of ACE inhibitors in the elderly, in blacks, and in women; yet they also leave most observers with an appropriate concern that it would be unethical to perform additional placebo-controlled trials of ACE inhibitors in such populations.The importance of studying older patients is highlighted by the marked influence of age on clinical outcomes. As age increased from 84 years, 1-year case fatality rates increased from 24.2% to 58.1%. Several factors may contribute to this finding in the elderly, including (1) variation in underlying pathophysiology, (2) high prevalence of comorbidities, (3) medication underutilization, and (4) reduced responsiveness or tolerance to treatments. Beyond uncertainties in drug efficacy in the elderly, clinical trials have taught us little about optimal dosing for this group of patients, in whom metabolism and clearance rates are often diminished, tolerability may be reduced, and drug-drug interactions are common. We are in desperate need of more aggressive investigation focusing on this patient population.Two exceptions illustrate the feasibility of molding trial populations to more closely match the overall heart failure population. The Evaluation of Losartan in the Elderly (ELITE) trials1516 achieved average ages of 74 and 71 years, respectively. Although a more representative age range does not assure that the trial's results can be generalized to every age segment, it makes subset analyses more credibly applicable to the elderly. If clinical trials are to represent a legitimate vehicle toward improving public health, then the principal rationale behind inclusion criteria must shift from expedience to representation of the populations at large.Previous investigations have provided conflicting observations regarding the relative prognosis for women and men with heart failure.2317 The study by MacIntyre et al1 provides novel insight into possible explanations for this discrepancy, because it contains a large enough cohort of younger women to demonstrate a complex interaction between sex, age, and prognosis. The 30-day mortality was lower for older women (≥65 years) and higher for younger women compared with their male counterparts. This finding may reflect a bimodal etiological distribution among women, with a high incidence of hypertensive, hypertrophic disease in older women18 and a preponderance of either premature coronary disease, with multiple coronary risks, or dilated cardiomyopathy in younger women.This finding reinforces the diverse nature of heart failure and emphasizes the need for improved sophistication of patient characterization within observational studies and clinical trials. Furthermore, we need to move beyond our rudimentary, descriptive understanding of sex differences in cardiovascular outcomes by developing imaginative designs for physiological studies and prospective trials to develop a more precise understanding of the mechanisms behind these differences.The mortality rates observed by MacIntyre et al1 are startlingly higher than those seen in most recent clinical trials, in which 1-year placebo-group mortality has ranged from 11% to 13%10111213 (Table). A number of factors are likely to contribute to these differences. The overall heart failure population is older and has a higher comorbidity rate than populations in clinical trials. Furthermore, an index hospitalization is not a typical entry criterion for long-term trials, and this requirement within the Scottish database selected a population with a worse short-term prognosis. Nevertheless, within the population at large, the effectiveness of medical management is probably lower than that within patients managed by clinical trial investigators. The poorer prognosis observed by MacIntyre et al1 may partly reflect the diminished efficacy of "proven" treatments in one or more population segments.Beyond potential differences in drug efficacy, proven treatments are underused. The most optimistic data suggest that ACE inhibitors are prescribed to only 55% of Medicare patients discharged with heart failure (73% among patients considered ideal candidates).19 An analysis of Medicare data from 10 large US states shows disturbing evidence for a downward trend in ACE inhibitor prescription for patients with increasing age,19 decreasing from 58.9% among patients 65 to 74 years to 49.6% among patients ≥85 years (77.9% to 67.0% among ideal candidates). Lower utilization rates for such drugs contribute to a worse prognosis across the broad population compared with the idealized clinical trial setting. Despite the independent nature of physicians, we must develop and accept processes to guarantee patients uniform utilization of drugs and procedures that are known to improve outcomes in a cost-effective manner.The good news is that prognosis seems to be improving. Between 1986 and 1995, median survival increased from 1.23 to 1.64 years. Factors other than treatment advances may have contributed to this improvement, including an evolving etiological spectrum of heart failure and changing thresholds for hospital admission. However, similar trends were not seen in 2 previously reported databases,35 in which the reporting periods ended before the publication of the Studies of Left Ventricular Dysfunction (SOLVD) trial. The observed improvement in survival probably reflects, at least in part, the impact of ACE inhibitors.There is a concerning trend toward less improvement in women (17% reduction in 30-day case fatality rate) compared with men (26% reduction). This finding further emphasizes the need to extend investigations of the basis for sex differences and to include a greater proportion of women in clinical trials.The study by MacIntyre et al1 suggests progress. We see the best evidence to date that improved heart failure treatment has resulted in improved outcomes. However, there is much more to do. Heart failure represents a growing epidemic in the elderly. Over 10 years of observation, MacIntyre et al1 found increases in the median age of patients admitted with heart failure from 76.0 to 79.0 years in women and from 70.7 to 73.0 years in men. As the median age in society rises, we will face a growing population of elderly heart failure patients for whom we will have no recourse but to offer management based on outcome trials performed predominantly in middle-aged, white men. We can do better. We can more aggressively pursue the physiological bases for potential sex, race, and age differences. We can design clinical trials out of need rather than expediency. And we can implement healthcare processes that deliver cost-effective treatments in a more uniform manner. The findings of MacIntyre et al1 represent important additions to our fund of knowledge regarding the epidemiology of heart failure. They also help identify deficiencies in our investigational and clinical practices, which we will need to correct if we are to maximally improve outcomes within this growing patient population.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association. Table 1. Patient Characteristics and Control Group Mortality in Selected Heart Failure Trials With the Greatest Impact on Current Treatment: Comparison With Findings of MacIntyre et al1StudyDrugClass1nMean Age, y% Men1-Year Mortality2CONSENSUS6EnalaprilIV253717152%SOLVD T7EnalaprilI–III2569618015.5%V-HeFT II8EnalaprilII, III8046110013%3SOLVD P9EnalaprilI, II422859895.1%Carvedilol US10CarvedilolII, III1094587711%DIG11DigoxinI–III6800637812.5%CIBIS 212BisoprololIII, IV2647618113.2%MERIT-HF13MetoprololII–IV3991647711.0%RALES14SpironolactoneIII,4 IV1663657325.3%Totals and weighted averages24 0496281MacIntyre et al166 547754744.5%CONSENSUS indicates Cooperative North Scandinavian Enalapril Survival Study; SOLVD, Studies of Left Ventricular Dysfunction; T, treatment trial; P, prevention trial; V-HeFT II, Vasodilator Heart Failure Trial II; DIG, Digitalis Investigation Group study; CIBIS, Cardiac Insufficiency Bisoprolol Study; MERIT-HF, Metoprolol controlled-release Randomized Intervention Trial in Heart Failure; and RALES, Randomized Aldactone Evaluation Study.1New York Heart Association class for most patients.2In control group.3Control group=hydralazine+isosorbide dinitrate.4Required class IV symptoms within 6 months of randomization.FootnotesCorrespondence to Marvin A. Konstam, MD, Division of Cardiology, New England Medical Center and Tufts University, Box 108, 750 Washington St, Boston MA 02111. E-mail [email protected] References 1 MacIntyre K, Capewell S, Stewart S, et al. Evidence of improving prognosis in heart failure: trends in case-fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation.2000; 102:1126–1131.CrossrefMedlineGoogle Scholar2 Bourassa MG, Gurne O, Bangdiwala SI, et al. Natural history and patterns of current practice in heart failure: the Studies of Left Ventricular Dysfunction (SOLVD) Investigators. J Am Coll Cardiol. 1993;22(4 Suppl A):14A–19A.Google Scholar3 Ho KKL, Anderson KM, Kannel WB, et al. Survival after the onset of congestive heart failure in Framingham heart study subjects. Circulation.1993; 88:107–115.CrossrefMedlineGoogle Scholar4 Ho KKL, Pinsky JL, Kannel WB, et al. The epidemiology of heart failure: the Framingham study. Circulation.1994; 89:506–507.CrossrefMedlineGoogle Scholar5 Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: trends in incidence and survival in a 10-year period. Arch Intern Med.1999; 159:29–34.CrossrefMedlineGoogle Scholar6 The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med.1987; 316:1429–1435.CrossrefMedlineGoogle Scholar7 The SOLVD Investigators. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med.1991; 325:293–302.CrossrefMedlineGoogle Scholar8 Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med.1991; 325:303–310.CrossrefMedlineGoogle Scholar9 The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med.1992; 327:685–691.CrossrefMedlineGoogle Scholar10 Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med.1996; 334:1349–1355.CrossrefMedlineGoogle Scholar11 The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med.1997; 336:525–533.CrossrefMedlineGoogle Scholar12 CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet.1999; 353:9–13.CrossrefMedlineGoogle Scholar13 MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet.1999; 353:2001–2007.CrossrefMedlineGoogle Scholar14 Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med.1999; 341:709–717.CrossrefMedlineGoogle Scholar15 Pitt B, Segal R, Martinez FA, et al, on behalf of the ELITE II investigators. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet.1997; 349:747–752.CrossrefMedlineGoogle Scholar16 Pitt B, Poole-Wilson PA, Segal R, et al, on behalf of the ELITE II investigators. Randomised trial of losartan versus captopril on mortality in patients with symptomatic heart failure: the Losartan Heart Failure Survival Study (ELITE II). Lancet.2000; 355:1582–1587.CrossrefMedlineGoogle Scholar17 Kimmelstiel CD, Konstam MA. Heart failure in women. Cardiology.1995; 86:304–309.CrossrefMedlineGoogle Scholar18 Topol EJ, Traill TA, Fortuin NJ. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med.1985; 312:277–283.CrossrefMedlineGoogle Scholar19 The Large State Peer Review Organization Consortium. Heart failure treatment with angiotensin-converting enzyme inhibitors in hospitalized Medicare patients in 10 large states. Arch Intern Med.1997; 157:1103–1108.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Jamiel A, Ebid M, Ahmed A, Ahmed D and Al-Mallah M (2017) The role of myocardial viability in contemporary cardiac practice, Heart Failure Reviews, 10.1007/s10741-017-9626-3, 22:4, (401-413), Online publication date: 1-Jul-2017. Li S, Zhang X, Cai G, Lin R, Jiang H, Chen J, Xu B and Huang W (2016) Prognostic Significance of Frontal QRS-T Angle in Patients with Idiopathic Dilated Cardiomyopathy, Chinese Medical Journal, 10.4103/0366-6999.187844, 129:16, (1904-1911), Online publication date: 20-Aug-2016. Martinez F (2016) Thyroid hormones and heart failure, Heart Failure Reviews, 10.1007/s10741-016-9556-5, 21:4, (361-364), Online publication date: 1-Jul-2016. Anderson E and Bosack R (2015) Anesthetic Considerations for Patients with Cardiovascular Disease Anesthesia complications in the dental office, 10.1002/9781119053231.ch5, (23-48) Subramaniam K (2015) Mechanical circulatory support, Best Practice & Research Clinical Anaesthesiology, 10.1016/j.bpa.2015.04.003, 29:2, (203-227), Online publication date: 1-Jun-2015. Bertoli S, Musetti C, Ciurlino D, Basile C, Galli E, Gambaro G, Iadarola G, Guastoni C, Carlini A, Fasciolo F, Borzumati M, Gallieni M and Stefania F (2014) Peritoneal Ultrafiltration in Refractory Heart Failure: A Cohort Study, Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 10.3747/pdi.2012.00290, 34:1, (64-70), Online publication date: 1-Jan-2014. Tuppin P, Cuerq A, de Peretti C, Fagot-Campagna A, Danchin N, Juillière Y, Alla F, Allemand H, Bauters C, Drici M, Hagège A, Jondeau G, Jourdain P, Leizorovicz A and Paccaud F (2014) Two-year outcome of patients after a first hospitalization for heart failure: A national observational study, Archives of Cardiovascular Diseases, 10.1016/j.acvd.2014.01.012, 107:3, (158-168), Online publication date: 1-Mar-2014. Selejan S, Pöss J, Hewera L, Kazakov A, Böhm M and Link A (2012) Role of receptor for advanced glycation end products in cardiogenic shock*, Critical Care Medicine, 10.1097/CCM.0b013e318241e536, 40:5, (1513-1522), Online publication date: 1-May-2012. Knecht K, Alosco M, Spitznagel M, Cohen R, Raz N, Sweet L, Colbert L, Josephson R, Hughes J, Rosneck J and Gunstad J (2012) Sleep Apnea and Cognitive Function in Heart Failure, Cardiovascular Psychiatry and Neurology, 10.1155/2012/402079, 2012, (1-7), Online publication date: 14-Jun-2012. Valchanov K and Arrowsmith J (2012) The role of venodilators in the perioperative management of heart failure, European Journal of Anaesthesiology, 10.1097/EJA.0b013e32835016be, 29:3, (121-128), Online publication date: 1-Mar-2012. BORIANI G, GASPARINI M, LANDOLINA M, LUNATI M, BIFFI M, SANTINI M, PADELETTI L, MOLON G, BOTTO G, DE SANTO T and VALSECCHI S (2011) Impact of Mitral Regurgitation on the Outcome of Patients Treated with CRT-D: Data from the InSync ICD Italian Registry, Pacing and Clinical Electrophysiology, 10.1111/j.1540-8159.2011.03280.x, 35:2, (146-154), Online publication date: 1-Feb-2012. Smith S and Abraham W (2011) Device Therapy in Advanced Heart Failure: What to Put In and What to Turn Off, Congestive Heart Failure, 10.1111/j.1751-7133.2011.00238.x, 17:5, (220-226), Online publication date: 1-Sep-2011. Pratt C (2010) Alternative Prevention and Treatment of Cardiovascular Disease, Part 2, Primary Care: Clinics in Office Practice, 10.1016/j.pop.2010.02.010, 37:2, (339-366), Online publication date: 1-Jun-2010. Herman W and Ferguson H (2010) Dental care for patients with heart failure, The Journal of the American Dental Association, 10.14219/jada.archive.2010.0282, 141:7, (845-853), Online publication date: 1-Jul-2010. Luedorff G, Kranig W, Grove R, Wolff E, Heimlich G and Thale J (2010) Improved success rate of cardiac resynchronization therapy implant by employing an active fixation coronary sinus lead, Europace, 10.1093/europace/euq078, 12:6, (825-829), Online publication date: 1-Jun-2010. Tigen K, Karaahmet T, Gurel E, Mutlu B, Basaran Y and Cevik C (2009) Prognostic Utility of Anemia and Pro-B-Type Natriuretic Peptide in Patients With Nonischemic Dilated Cardiomyopathy and Normal Renal Function, The American Journal of the Medical Sciences, 10.1097/MAJ.0b013e31818128b5, 337:2, (109-115), Online publication date: 1-Feb-2009. Wykrzykowska J and Carrozza J (2010) Percutaneous Management of Valvular Heart Disease Device Therapy in Heart Failure, 10.1007/978-1-59745-424-7_12, (305-337), . Zuccalà G, Colloca G and Tosato M (2009) Congestive Heart Failure/Heart Transplant Neurovascular Neuropsychology, 10.1007/978-0-387-70715-0_11, (151-162), . Laguens R and Crottogini A (2009) Cardiac regeneration: the gene therapy approach, Expert Opinion on Biological Therapy, 10.1517/14712590902806364, 9:4, (411-425), Online publication date: 1-Apr-2009. Jacobson A, Lombard J, Banerjee G and Camici P (2009) 123I-mIBG Scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: Design of two prospective multicenter international trials, Journal of Nuclear Cardiology, 10.1007/s12350-008-9008-2, 16:1, (113-121), Online publication date: 1-Feb-2009. Costantino G, Rusconi A, Duca P, Guzzetti S, Bossi I, Del Medico M, Pisano G, Bulgheroni M, Solbiati M, Furlan R and Montano N (2008) Eligibility criteria in heart failure randomized controlled trials: a gap between evidence and clinical practice, Internal and Emergency Medicine, 10.1007/s11739-008-0180-9, 4:2, (117-122), Online publication date: 1-Apr-2009. Boriani G, Gasparini M, Landolina M, Lunati M, Biffi M, Santini M, Padeletti L, Molon G, Botto G, De Santo T and Valsecchi S (2009) Effectiveness of cardiac resynchronization therapy in heart failure patients with valvular heart disease: comparison with patients affected by ischaemic heart disease or dilated cardiomyopathy. The InSync/InSync ICD Italian Registry, European Heart Journal, 10.1093/eurheartj/ehp226, 30:18, (2275-2283), Online publication date: 2-Sep-2009. Hombach V, Merkle N, Torzewski J, Kraus J, Kunze M, Zimmermann O, Kestler H and Wohrle J (2009) Electrocardiographic and cardiac magnetic resonance imaging parameters as predictors of a worse outcome in patients with idiopathic dilated cardiomyopathy, European Heart Journal, 10.1093/eurheartj/ehp293, 30:16, (2011-2018), Online publication date: 2-Aug-2009. Chen K, Li Y, Huang T and Li Y (2008) Neural remodeling may partly contribute to the abnormality of excitation–contraction coupling in heart failure, Medical Hypotheses, 10.1016/j.mehy.2007.04.019, 70:1, (112-116), Online publication date: 1-Jan-2008. Akinbamowo A, Salzberg D and Weir M (2008) Renal Consequences of Prostaglandin Inhibition in Heart Failure, Heart Failure Clinics, 10.1016/j.hfc.2008.03.002, 4:4, (505-510), Online publication date: 1-Oct-2008. Beaumont J, Arias T, López B, González A, Ravassa S, Hermida N, Querejeta R and Díez J (2007) Avances en cardiopatía hipertensiva. Mecanismos de remodelado implicados en la transición de la hipertrofia a la insuficiencia cardiaca, Revista Española de Cardiología Suplementos, 10.1016/S1131-3587(07)75252-4, 7:6, (14F-21F), Online publication date: 1-Jan-2007. Jessup M and Brozena S (2007) Guidelines for the Management of Heart Failure: Differences in Guideline Perspectives, Cardiology Clinics, 10.1016/j.ccl.2007.08.004, 25:4, (497-506), Online publication date: 1-Nov-2007. Beanlands R, Nichol G, Huszti E, Humen D, Racine N, Freeman M, Gulenchyn K, Garrard L, deKemp R, Guo A, Ruddy T, Benard F, Lamy A and Iwanochko R (2007) F-18-Fluorodeoxyglucose Positron Emission Tomography Imaging-Assisted Management of Patients With Severe Left Ventricular Dysfunction and Suspected Coronary Disease, Journal of the American College of Cardiology, 10.1016/j.jacc.2007.09.006, 50:20, (2002-2012), Online publication date: 1-Nov-2007. Tigen K, Karaahmet T, Kahveci G, Tanalp A, Bitigen A, Fotbolcu H, Bayrak F, Mutlu B and Basaran Y (2007) N-Terminal Pro Brain Natriuretic Peptide to Predict Prognosis in Dilated Cardiomyopathy with Sinus Rhythm, Heart, Lung and Circulation, 10.1016/j.hlc.2007.02.083, 16:4, (290-294), Online publication date: 1-Aug-2007. Kestler H, Kraus J, Hoher M, Hombach V and Wohrle J (2007) Prognostic significance of electrocardiogram and cine magnetic resonance imaging parameters in patients with idopathic dilated cardiomyopathy 2007 34th Annual Computers in Cardiology Conference, 10.1109/CIC.2007.4745425, 978-1-4244-2533-4, (77-80) Oyama M, Sisson D, Prošek R, Bulmer B, Luethy M and Fuentes V (2007) Carvedilol in Dogs with Dilated Cardiomyopathy, Journal of Veterinary Internal Medicine, 10.1111/j.1939-1676.2007.tb01949.x, 21:6, (1272-1279), Online publication date: 1-Nov-2007. Bulwer B, Solomon S and Janardhanan R Echocardiographic Assessment of Ventricular Systolic Function Essential Echocardiography, 10.1007/978-1-59259-977-6_5, (89-117) Haase H, Dobbernack G, Tünnemann G, Karczewski P, Cardoso C, Petzhold D, Schlegel W, Lutter S, Pierschalek P, Behlke J and Morano I (2006) Minigenes encoding N‐terminal domains of human cardiac myosin light chain‐1 improve heart function of transgenic rats, The FASEB Journal, 10.1096/fj.05-5414com, 20:7, (865-873), Online publication date: 1-May-2006. Javier Trujillo-Santos A, Domingo-González S, Gonzalo-Blanquer J, Perea-Milla E, Jiménez-Puente A and García-Alegría J (2006) Indicadores de calidad relacionados con el reingreso y la muerte precoces tras la hospitalización por insuficiencia cardíaca, Medicina Clínica, 10.1157/13084534, 126:5, (165-169), Online publication date: 1-Feb-2006. van Jaarsveld C, Ranchor A, Kempen G, Coyne J, van Veldhuisen D and Sanderman R (2005) Epidemiology of heart failure in a community-based study of subjects aged ≥57 years: Incidence and long-term survival, European Journal of Heart Failure, 10.1016/j.ejheart.2005.04.012, 8:1, (23-30), Online publication date: 1-Jan-2006. Makaritsis K, Liakopoulos V, Leivaditis K, Eleftheriadis T and Stefanidis I (2009) Adaptation of Renal Function in Heart Failure, Renal Failure, 10.1080/08860220600839522, 28:7, (527-535), Online publication date: 1-Jan-2006. Formiga F, Chivite D, Solé A, Manito N, Ramon J and Pujol R (2006) Functional outcomes of elderly patients after the first hospital admission for decompensated heart failure (HF), Archives of Gerontology and Geriatrics, 10.1016/j.archger.2005.10.010, 43:2, (175-185), Online publication date: 1-Sep-2006. Lenzen M, Boersma E, Scholte op Reimer W, Balk A, Komajda M, Swedberg K, Follath F, Jimenez-Navarro M, Simoons M and Cleland J (2005) Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure, European Heart Journal, 10.1093/eurheartj/ehi499, 26:24, (2706-2713), Online publication date: 1-Dec-2005. Zuccalà G, Onder G, Marzetti E, Monaco M, Cesari M, Cocchi A, Carbonin P and Bernabei R (2004) Use of angiotensin-converting enzyme inhibitors and variations in cognitive performance among patients with heart failure, European Heart Journal, 10.1093/eurheartj/ehi058, 26:3, (226-233), Online publication date: 1-Feb-2005. López Salazar B, González Miqueo A, Laviades Álvarez C, Querejeta Iraola R and Díez Martínez J (2005) Avances en el diagnóstico de la cardiopatía hipertensiva, Hipertensión, 10.1016/S0212-8241(05)71570-X, 22:6, (259-265), Online publication date: 1-Sep-2005. López Salazar B, González Miqueo A, Laviades Álvarez C, Querejeta Iraola R and Díez Martíneza J (2005) Avances en el diagnóstico de la cardiopatía hipertensiva, Hipertensión y Riesgo Vascular, 10.1016/S1889-1837(05)71559-2, 22:6, (259-265), Online publication date: 1-Jan-2005. Zuccalà G, Marzetti E, Cesari M, Lo Monaco M, Antonica L, Cocchi A, Carbonin P and Bernabei R (2005) Correlates of cognitive impairment among patients with heart failure: Results of a multicenter survey, The American Journal of Medicine, 10.1016/j.amjmed.2005.01.030, 118:5, (496-502), Online publication date: 1-May-2005. Hobbs R and Tang W (2005) Current and future uses of nesiritide, Future Cardiology, 10.1517/14796678.1.2.145, 1:2, (145-155), Online publication date: 1-Mar-2005. Parissis J, Filippatos G, Farmakis D, Adamopoulos S, Paraskevaidis I and Kremastinos D (2005) Levosimendan for the treatment of acute heart failure syndromes, Expert Opinion on Pharmacotherapy, 10.1517/14656566.6.15.2741, 6:15, (2741-2751), Online publication date: 1-Dec-2005. Herzog C, Muster H, Li S and Collins A (2004) Impact of congestive heart failure, chronic kidney disease, and anemia on survival in the Medicare population, Journal of Cardiac Failure, 10.1016/j.cardfail.2004.03.003, 10:6, (467-472), Online publication date: 1-Dec-2004. Camici P and Rimoldi O (2009) The contribution of hibernation to heart failure, Annals of Medicine, 10.1080/07853890410035368, 36:6, (440-447), Online publication date: 1-Jan-2004. von Harsdorf R, Poole-Wilson P and Dietz R (2004) Regenerative capacity of the myocardium: implications for treatment of heart failure, The Lancet, 10.1016/S0140-6736(04)16006-6, 363:9417, (1306-1313), Online publication date: 1-Apr-2004. Iyengar S, Feldman D, Trupp R and Abraham W (2005) Nesiritide for the treatment of congestive heart failure, Expert Opinion on Pharmacotherapy, 10.1517/14656566.5.4.901, 5:4, (901-907), Online publication date: 1-Apr-2004. Clark R, McLennan S, Dawson A, Wilkinson D and Stewart S (2004) Uncovering a Hidden Epidemic: A Study of the Current Burden of Heart Failure in Australia, Heart, Lung and Circulation, 10.1016/j.hlc.2004.06.007, 13:3, (266-273), Online publication date: 1-Sep-2004. De Geest S, Scheurweghs L, Reynders I, Pelemans W, Droogné W, Van Cleemput J, Leventhal M and Vanhaecke J (2003) Differences in psychosocial and behavioral profiles between heart failure patients admitted to cardiology and geriatric wards, European Journal of Heart Failure, 10.1016/S1388-9842(02)00298-2, 5:4, (557-567), Online publication date: 1-Aug-2003. Zuccalà G, Pedone C, Cesari M, Onder G, Pahor M, Marzetti E, Lo Monaco M, Cocchi A, Carbonin P and Bernabei R (2003) The effects of cognitive impairment on mortality among hospitalized patients with heart failure, The American Journal of Medicine, 10.1016/S0002-9343(03)00264-X, 115:2, (97-103), Online publication date: 1-Aug-2003. Jessup M and Brozena S (2003) Heart Failure, New England Journal of Medicine, 10.1056/NEJMra021498, 348:20, (2007-2018), Online publication date: 15-May-2003. Jessup M (2003) The less familiar face of heart failure**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology., Journal of the American College of Cardiology, 10.1016/S0735-1097(02)02697-9, 41:2, (224-226), Online publication date: 1-Jan-2003. Konstam M (2003) Colloid osmotic pressure, Journal of the American College of Cardiology, 10.1016/S0735-1097(03)00764-2, 42:4, (717-718), Online publication date: 1-Aug-2003. Konstam M (2003) Improving clinical outcomes with drug treatment in heart failure: what have trials taught?, The American Journal of Cardiology, 10.1016/S0002-9149(02)03374-X, 91:6, (9-14), Online publication date: 1-Mar-2003. Piller L, Davis B, Cutler J, Cushman W, Wright J, Williamson J, Leenen F, Einhorn P, Randall O, Golden J and Haywood L (2002) Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone, Current Controlled Trials in Cardiovascular Medicine, 10.1186/1468-6708-3-10, 3:1, Online publication date: 1-Dec-2002. Permanyer Miralda G, Soriano N, Brotons C, Moral I, Pinar J, Cascant P, Ribera A, Soler-Soler J and Morlans M (2002) Características basales y determinantes de la evolución en pacientes ingresados por insuficiencia cardíaca en un hospital general, Revista Española de Cardiología, 10.1016/S0300-8932(02)76664-5, 55:6, (571-578), Online publication date: 1-Jan-2002. Stewart S, MacIntyre K, Hole D, Capewell S and McMurray J (2001) More 'malignant' than cancer? Five-year survival following a first admission for heart failure, European Journal of Heart Failure, 10.1016/S1388-9842(00)00141-0, 3:3, (315-322), Online publication date: 1-Jun-2001. Konstam M (2001) Relating quality of care to clinical outcomes in heart failure: In search of the missing link, Journal of Cardiac Failure, 10.1054/jcaf.2001.30132, 7:4, (299-301), Online publication date: 1-Dec-2001. Mehra M and Uber P (2001) THE DILEMMA OF LATE-STAGE HEART FAILURE, Cardiology Clinics, 10.1016/S0733-8651(05)70249-6, 19:4, (627-636), Online publication date: 1-Nov-2001. Tereschenko S, Zhirov I and Nakonechnikov S (2012) DYAGNOSIS AND TREATMENT OF CARDIAC PULMONARY OEDEMA, Eurasian heart journal, 10.38109/2225-1685-2012-2-6-15:2, (6-15) Nicotera G, Sferrazza G, Serafino A and Pierimarchi P (2019) The Iterative Development of Medicines Through the European Medicine Agency's Adaptive Pathway Approach, Frontiers in Medicine, 10.3389/fmed.2019.00148, 6 September 5, 2000Vol 102, Issue 10 Advertisement Article InformationMetrics Copyright © 2000 by American Heart Associationhttps://doi.org/10.1161/01.CIR.102.10.1076 Originally publishedSeptember 5, 2000 Keywordsmortalitysurvivaltrialsheart failureEditorialsPDF download Advertisement
Referência(s)